Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels. by Holmes, Michael V et al.
144
The secretory phospholipases (sPLA2s) are a family of enzymes that hydrolyse phospholipids on lipoprotein 
particles, initially in the plasma, leading to the modification 
of low-density lipoproteins (LDLs) to small, dense, proath-
erogenic LDL particles that can transcytose the endothelial 
layer of the arterial wall.1 Further modification of these inti-
mal apolipoprotein B–containing lipoproteins,2 by sPLA2s in 
the arterial wall, leads to their accumulation and retention 
on the proteoglycans within the intima, a proatherosclerotic 
process.3 Additionally, by hydrolyzing lipoprotein phospho-
lipids, sPLA2s generate lysophospholipid and nonesteri-
fied free fatty acids, such as arachidonic acid, a precursor 
of eicosanoids and leukotreines4,5 that are proinflammatory 
cytokines.
Background—Secretory phospholipase A2 (sPLA2) enzymes are considered to play a role in atherosclerosis. sPLA2 activity 
encompasses several sPLA2 isoenzymes, including sPLA2-V. Although observational studies show a strong association 
between elevated sPLA2 activity and CHD, no assay to measure sPLA2-V levels exists, and the only evidence linking 
the sPLA2-V isoform to atherosclerosis progression comes from animal studies. In the absence of an assay that directly 
quantifies sPLA2-V levels, we used PLA2G5 mRNA levels in a novel, modified Mendelian randomization approach to 
investigate the hypothesized causal role of sPLA2-V in coronary heart disease (CHD) pathogenesis.
Methods and Results—Using data from the Advanced Study of Aortic Pathology, we identified the single-nucleotide 
polymorphism in PLA2G5 showing the strongest association with PLA2G5 mRNA expression levels as a proxy for 
sPLA2-V levels. We tested the association of this SNP with sPLA2 activity and CHD events in 4 prospective and 14 case–
control studies with 27 230 events and 70 500 controls. rs525380C>A showed the strongest association with PLA2G5 
mRNA expression (P=5.1×10−6). There was no association of rs525380C>A with plasma sPLA2 activity (difference in 
geometric mean of sPLA2 activity per rs525380 A-allele 0.4% (95% confidence intervals [−0.9%, 1.6%]; P=0.56). In 
meta-analyses, the odds ratio for CHD per A-allele was 1.02 (95% confidence intervals [0.99, 1.04]; P=0.20).
Conclusions—This novel approach for single-nucleotide polymorphism selection for this modified Mendelian randomization 
analysis showed no association between rs525380 (the lead single-nucleotide polymorphism for PLA2G5 expression, a 
surrogate for sPLA2-V levels) and CHD events. The evidence does not support a causal role for sPLA2-V in CHD.  (Circ 
Cardiovasc Genet. 2014;7:144-150.)
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Three sPLA2 isoenzymes have been identified in human 
atherosclerotic lesions: sPLA2-IIa, sPLA2-V, and sPLA2-X.3 
It is thought that sPLA2-V may contribute to the quantita-
tive trait sPLA2 activity, a composite measure of sPLA2-IIa, 
-V, and -X,6 although no direct biological proof exists. There 
is converging evidence from both the European Prospective 
Investigation into Cancer and Nutrition (EPIC)-Norfolk study6 
and Global Registry of Acute Coronary Events (GRACE),7 
a study of patients with acute coronary syndrome[15], that 
sPLA2 activity shows stronger association with cardiovascular 
risk than sPLA2-IIa levels alone. This provides some indirect 
evidence that sPLA2 activity might encompass more than just 
sPLA2-IIa, and this identifies sPLA2-V as a potential con-
tributor to CHD risk in humans. Although a large body of 
observational studies support the relationship between higher 
sPLA2-IIa levels and risk of CHD in humans,7–11 no such studies 
exist for sPLA2-V. A specific ELISA assay exists that enables 
the quantification of sPLA2-IIa levels, but there is currently 
no assay to specifically measure sPLA2-V levels. Despite the 
lack of observational studies in humans for sPLA2-V, animal 
studies report a proatherogenic role for sPLA2-V as well as 
-IIa, showing increased susceptibility to atherosclerosis in 
sPLA2-V (Pla2g5)12,13 and sPLA2-IIa (Pla2g2a) transgenic 
mice.14,15 Studies of human tissue also indicate that sPLA2-
V is expressed in human endothelial cells, macrophages, and 
lipid-loaded macrophages.16 Suggested mechanisms by which 
sPLA2-V is thought to increase risk of CHD include increas-
ing the entrapment of LDLs in the atherosclerotic plaque and 
modification of LDLs to encourage generation of foam cells.16
The specific catalytic dyad found in sPLA2 enzymes17 
makes them suitable drug targets, and indeed an sPLA2 inhibi-
tor has been developed. The drug varespladib, with a pri-
mary target of sPLA2-IIa, also inhibits sPLA2-V.18 However, 
because the exact contribution of sPLA2-V to plasma sPLA2 
activity is unknown, it is challenging to infer the nature of the 
relationship between sPLA2-V and CHD events.
Genetics provides a powerful tool to examine whether a 
relationship between a biomarker and a disease outcome is 
likely to be causal. This process, called Mendelian randomiza-
tion (MR), makes use of a genetic variant that associates with 
the biomarker of interest as a means to investigate whether the 
biomarker is causally related to disease.19 There are 3 steps 
in traditional MR analysis, often referred to as MR triangula-
tion. The first side of the triangle usually is the starting point 
of the analysis and arises from observational studies, which 
report the association of the biomarker with CHD, in this case 
it would be sPLA2-V levels. However, in the absence of mea-
sures of plasma sPLA2-V levels, observational studies report 
the association of elevated levels of the composite measure of 
sPLA2 activity with CHD risk.6,7 The second side of the MR 
triangle validates the association of the genetic variant with the 
biomarker of interest. In this modified MR study, the absence 
of a specific assay to quantify sPLA2-V levels motivated us to 
pursue a novel approach that exploited the availability of vas-
cular tissue mRNA expression of PLA2G5 (the gene encoding 
sPLA2-V) as a proxy for sPLA2-V levels, and for this we identi-
fied a common PLA2G5 gene variant most strongly associated 
with PLA2G5 mRNA expression. We feel this novel approach 
is justified because a recent study we performed for sPLA2-IIa 
found that the single-nucleotide polymorphism (SNP) show-
ing strongest association with PLA2G2A mRNA was in strong 
linkage disequilibrium with the SNP that showed strongest 
association with sPLA2-IIa (a specific assay for sPLA2-IIa).20 
Finally, to validate whether the biomarker is causal, the MR 
triangle is completed by examining the association of the 
PLA2G5 variant with CHD risk and comparing this value to 
the observational estimate for a similar difference in biomarker.
Methods
SNP Selection for Mendelian Randomization Using 
mRNA Expression
We searched publicly available eQTL data sets to identify SNPs in 
PLA2G5 associated with eQTL effects at genome-wide significance 
in circulating cells in blood.21–24 This did not identify any associations, 
and we therefore focused on mRNA expression in tissue samples in our 
own data set. We used the Advanced Study of Aortic Pathology (ASAP) 
(n=272) as a source of PLA2G5 mRNA expression. Individuals under-
going valve surgery had tissue biobanked from liver (n=212), mamma-
ry artery intima-media (n=89), ascending aorta intima-media (n=138), 
aorta adventitia (n=133), and heart (n=127), and subsequently mRNA 
levels extracted. mRNA levels were quantified using Affymetrix Gene 
Chip Human Exon 1.0 ST expression arrays, and DNA was genotyped 
using Illumina Human 610 W-Quad Bead array.25 We investigated the 
association between SNPs in and within 200 kb of the PLA2G5 gene 
with mRNA expression of PLA2G5 and selected the SNP that showed 
the strongest differential association with PLA2G5 expression levels. 
SNPs with a call rate <80% or Hardy–Weinberg χ2 statistic >3.84 were 
excluded. The overall call rate per SNP was 99.84%. Twelve samples 
were genotyped in duplicate, and the concordance was 99.99%. The 
rs525380 SNP was in Hardy–Weinberg equilibrium (P=0.54) and had 
a call rate of 100%.
Association of the Gene Variant With Nonindex 
mRNA Expression and sPLA2 Activity
To investigate the specificity of our genetic variant, we examined the 
relationship between the SNPs with mRNA levels of PLA2G2A and 
PLA2G10. To gauge insight into the relative contribution of  sPLA2-V 
to sPLA2 activity, we investigated the per-allele association of the 
SNPs with sPLA2 activity in EPIC-Norfolk (measured by a selective 
fluorometric assay).7
Genotyping of rs525380
The lead SNP in the analysis, rs525380, was present on various ge-
nome wide association studies platforms used by the CARDioGRAM 
studies.26 For  EPIC-Netherlands, Whitehall II, and Women’s Health 
Initiative, genotyping was performed using the IBC CardioChip array 
(Illumina HumanCVD).27 For the remaining study (EPIC-Norfolk), 
the rs525380 SNP was genotyped using TaqMan technology (Applied 
Biosciences, ABI, Warrington, UK; Table I in the Data Supplement). 
In each study, rs525380 was in Hardy–Weinberg equilibrium with 
call rates >97%.
Association of the Gene Variant With LDL-C Levels
We previously reported an association of PLA2G5 SNPs with 
 LDL-cholesterol (LDL-C) levels in a small study of patients with 
type 2 diabetes mellitus.28 To investigate whether LDL-C may rep-
resent a mediator between sPLA2-V and CHD, we looked up the as-
sociation of rs525380 in a recent large gene-centric analysis of 32 
studies including 66 240 individuals of European ancestry.29
Association of the Gene Variant With CHD Events
Data from 18 studies were used in the analysis of the association 
between the PLA2G5 lead SNP and CHD risk, comprising 3 nested 
case–control studies (Women’s Health Initiative,30 EPIC-Norfolk,8 
and EPIC-Netherlands),31 1 prospective cohort (Whitehall II),32 and 
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14 case–control studies (participants in the CARDIoGRAM GWA 
meta-analysis of coronary artery disease [CAD]).26 All studies were 
approved by their institutional review committees, and subjects gave 
informed consent.
These studies are described in Table I in the Data Supplement and 
the details of the CARDIoGRAM consortium in Table II in the Data 
Supplement.
Statistical Analysis
All gene expression values were log2 transformed before analysis as 
part of the microarray preprocessing algorithm. Association strength 
between genotype and gene expression levels were calculated using a 
linear regression model with the gene expression as response variable 
and the genotype recoded numerically (as 0, 1, and 2) as the explana-
tory variable. A Bonferroni-adjusted P value threshold of P<8.4×10−5 
was taken as the level of significance for the association of SNPs 
with mRNA expression. The mRNA analysis was performed using 
R 2.13.0 and Bioconductor.
sPLA2 activity was log(e) transformed before analysis be-
cause of a skewed distribution. We used an additive model for 
the genetic association analysis of rs525380 with sPLA2 activ-
ity and CHD events. The univariate per-minor A-allele estimates 
for the rs525380 variant with sPLA2 activity, and CHD events 
were estimated using linear and logistic regression, respectively. 
Study-level estimates (beta coefficients or log odds with their re-
spective standard errors) were pooled using fixed-effects (inverse 
variance) meta-analysis, and heterogeneity was quantified using 
the I2 statistic. For the association of rs525380 with sPLA2 activ-
ity, summary estimates were exponentiated and converted into a 
percentage difference in the geometric mean. All analyses, unless 
otherwise stated, were performed using Stata 12.1 (StataCorp, 
College Station, TX).
Results
Identification of the SNP Showing the Strongest 
Association With PLA2G5 Expression
The SNP showing the strongest association with PLA2G5 
mRNA expression was rs525380 at P=5.1×10−6 (n=272, 
Figure 1), which surpassed our Bonferroni-adjusted P value 
threshold. PLA2G5 was most highly expressed in the heart 
(Figure 2), where it was among the top 11% most highly 
expressed genes and in the top 50% of expression in other 
investigated tissues (mammary artery, liver, aorta media, and 
adventitia). The rs525380C>A was associated with the stron-
gest differential mRNA expression of PLA2G5 in the aortic 
adventitia explaining 14.5% of the PLA2G5 mRNA variance 
(n=133, Figure 2; Figure I in the Data Supplement); the rare 
A-allele was associated with 37.6% higher mRNA levels 
than the common C allele. Associations of rs525380 with 
PLA2G5 mRNA expression were also identified in the aortic 
media and mammary artery (P<0.001; Figure 2). The regional 
plot for rs525380, showing the linkage disequilibrium (LD) 
with SNPs in the vicinity, is presented in Figure I in the Data 
Supplement. This plot shows that the LD falls off around the 
lead SNP, rs525380, in PLA2G5 and shows little LD with 
PLA2G2A SNPs, with R2≤0.2.
Bioinformatic Analysis of rs525380
rs525380 is located ≈12.5 kb downstream of the PLA2G5 tran-
scription start site within a potential enhancer motif, experi-
mentally determined by DNaseI-seq and FAIRE-seq open 
chromatin marks (liver and vascular cells), and by ChIP-seq 
for the transcription factor GATA-2 (UCSC Genome Browser 
GRCh37/hg1933; Figure II in the Data Supplement), suggest-
ing rs525380 may be functional, potentially playing a distal 
regulatory role and altering PLA2G5 expression.
Association of PLA2G5 SNPs With PLA2G2A 
and PLA2G10 mRNA Expression Levels and  
sPLA2 Activity
We next examined the association of PLA2G5 rs525380 with 
PLA2G2A (lying head to tail with PLA2G5 on chr1) and 
PLA2G10 (chr10) mRNA expression levels. We did not observe 
an association of rs525380 and PLA2G2A mRNA expression in 
vascular tissues, but we did identify an association of rs525380 
with liver PLA2G2A mRNA expression (n=212, P=0.001, Fig-
ure III in the Data Supplement). rs525380 showed no associa-
tion with PLA2G10 mRNA expression in any tissue (P>0.05 
for all associations).
There was no association between the A-allele of rs525380 
and plasma sPLA2 activity (n=3095, 0.4% difference in 
geometric mean per A-allele of rs525380; 95% confidence 
interval [CI] [−0.9%, 1.6%]; P=0.56).
Association of rs525380 With LDL-C Levels
A look-up in a large meta-analysis across 32 studies29 yielded a 
pooled per A-allele estimate of 0.002 mmol/l (95% CI [−0.008, 
0.012]) difference in LDL-C in 66 240 individuals (P=0.71), thus 
showing no association between rs525380 and LDL-C levels.
Association of rs525380 With CHD Events
The pooled estimate of the association of rs525380 with CHD 
events in meta-analysis of 18 studies with 27 230 CHD events 
in 97 730 individuals did not identify any evidence of associa-
tion. The per-A-allele estimate was OR 1.02 (95% CI [0.99, 
Figure 1. Manhattan plot of the association between single-
nucleotide polymorphisms in the PLA2G5 region and PLA2G5 
mRNA expression by tissue type. rs525380 A>C showed the 
strongest association with PLA2G5 mRNA expression in the 
aorta adventitia (P=5.05×10−6). The black horizontal line above 
the scale represents the position of PLA2G5. Total number of 
individuals providing tissue samples for analysis=272 (samples 
available for each tissue: mammary artery 89, liver 212, aorta 
med 138, aorta adventitia 133, heart 127).
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1.04]), and the heterogeneity was low (I2=0%; 95% CI [0%, 
48%]; Figure 3). When we restricted the analysis to only large 
studies with >1000 CHD events (11 studies with 22 757 cases 
in 85 494 individuals), the estimate remained unchanged (OR 
1.01; 95% CI [0.99, 1.04]).
Discussion
We performed a modified MR analysis to evaluate whether the 
relationship between sPLA2-V and CHD events is likely to be 
causal. In the absence of a suitable assay to directly quantify 
sPLA2-V levels, we took the novel approach of using vascu-
lar mRNA expression levels of the gene encoding sPLA2-V, 
PLA2G5, as a proxy measure. We found PLA2G5 to be highly 
expressed in all available tissues, being among the top 11% 
genes expressed in the heart and in the top 50% of expression 
in other investigated tissues. We identified an SNP that sur-
passed the predefined Bonferroni-adjusted P value threshold 
for association with PLA2G2A mRNA expression, explain-
ing 14% of the variance in PLA2G5 mRNA levels. We took 
this genetic variant forward to investigate the association with 
CHD in a large collection of studies. In analysis of 27 230 
Figure 3. Forest plot of 
the association of PLA2G5 
rs525380 (per A-allele) with 
CHD in 27 230 cases in a total 
of 97 730 individuals. When 
limited to studies with <1000 
CHD events, the odds ratio 
(OR) was 1.04 (95% CI [0.97, 
1.11]) with an I2 of 31% (95% 
confidence intervals [CI] {0% to 
71%]). For studies with >1000 
CHD events, the OR was 1.01 
(95% CI [0.99, 1.04]) with an I2 
of 0% (95% CI [0% to 43%]).
Figure 2. Overall expression of all 
 probe-sets and the differential expression 
of PLA2G5 rs525380 C>A with PLA2G5 
mRNA in the 5 tissue types. AMed indi-
cates dilated and nondilated ascending 
aorta intima-media; MMed, mammary 
artery intima-media; and aorta ADV, aorta 
adventitia. The samples sizes for samples 
from individuals with the genotypes CC,  
CA, and AA are as follows: heart 43/68/16, 
MMed 21/51/17, AMed 44/70/24, aorta 
ADV 38/73/22, and liver 59/120/32.
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CHD events across 97 730 total individuals, the SNP was not 
associated with CHD, suggesting that sPLA2-V may not be 
causally involved in CHD pathogenesis.
We recently used a similar technique for SNP selection 
when we investigated the role of sPLA2-IIa in CHD.20 In the 
case of sPLA2-IIa, we did have access to a trait that directly 
quantified circulating levels of sPLA2-IIa. We showed that 
the SNP showing the strongest association with circulating 
sPLA2-IIa levels was in high linkage disequilibrium with the 
SNP showing the strongest association with PLA2G2A mRNA 
expression. This serves to justify the method we used here: 
that is, we assume that if we could quantify circulating sPLA2-
V levels, we would find that the SNP that showed the strongest 
association with sPLA2-V levels would also show the stron-
gest association with PLA2G5 mRNA expression.
mRNA expression is considered a good proxy for its 
encoded protein, although it might only reflect a proportion 
of protein expression because post-transcriptional and post-
translational modifications may further influence protein lev-
els.34 Thus, the association of rs525380 with PLA2G5 mRNA 
in vascular tissue may be a good marker of sPLA2-V expres-
sion. This is supported by immunohistochemistry and in 
situ hybridization of sPLA2-V in human atherosclerotic aor-
tas showing that sPLA2-V protein expression was limited to 
smooth muscle cells, and this correlated well with PLA2G5 
mRNA expression.35
One of the limitations of our study is the lack of observa-
tional data on the association of sPLA2-V levels and risk of 
CHD, limited by the absence of an available sPLA2-V ELISA. 
PLA2G5 mRNA expression measures are limited by availabil-
ity of data sets with tissue mRNA expression in individuals 
with and without CHD. The lack of a quantitative trait also 
means that a formal Mendelian triangulation analysis is not 
possible.19 However, the genetic analysis that we present 
is a form of MR as the SNP (rs525380) will, according to 
Mendel’s second law, be randomized at conception, mean-
ing that individuals grouped by rs525380 genotype should be 
equal in all respects apart from exposure to differing PLA2G5 
mRNA expression levels. Several animal studies support an 
atherosclerotic role of sPLA2-V,12,13,36,37 although we accept 
that positive findings from animal studies do not always trans-
late into meaningful advances in combatting human disease.38 
Even in the absence of availability of an observational quan-
tification of the association of sPLA2-V (or for that matter 
PLA2G5 mRNA) with CHD events in humans, our genetic 
findings show that if such an association were to exist, it 
would most likely be attributable to confounding and reverse 
causality rather than a causal relationship. We have made the 
assumption that vascular expression of sPLA2-V is a likely 
proatherogenic mediator, and therefore we have considered 
vascular PLA2G5 mRNA as a good proxy for circulating 
levels of sPLA2-V levels. Our findings do not support those 
from animal studies and suggest sPLA2-V is not an important 
cause of CHD in humans. The outcome of this study is in part 
validated by the phase III Vista 16 trial of varespladib (a drug 
that inhibits sPLA2-IIA, sPLA2-V, and sPLA2-X), prematurely 
terminated because of lack of efficacy.39
Because we had no measure of sPLA2-V levels, we were 
unable to estimate the effect of the PLA2G5 SNP on  sPLA2-V 
levels, and without an estimate of the observed association 
between sPLA2-V and CHD to obtain the expected effect size, 
we were unable to perform a power calculation. However, for 
comparison, in our MR analysis of sPLA2-IIA,20 in studies set 
in the general population, we had a total of 15 534 incident 
and prevalent cardiovascular events out of a total of 74 683 
individuals. In this current study, we almost doubled the num-
ber of events with 27 230 events in 97 730 individuals. With 
an OR of 1.02 (95% CI [0.99, 1.04]) between rs525380 and 
CHD, we are able to exclude a large effect of the SNP on 
CHD. Furthermore, the I2 value of 0%, indicating low het-
erogeneity, means that the values reported in the individual 
studies included in this meta-analysis were similar (ie, low 
between-study heterogeneity), adding further confidence to a 
true negative finding.
Plasma sPLA2 activity is suggested to represent a com-
posite of the activities of the -IIa, -V, and -X isoenzymes.6 
However, currently no experimental evidence supports this. In 
a recent MR investigation of  sPLA2-IIa,20 we reported that the 
SNP showing the strongest association with sPLA2-IIa levels 
explained 31% of PLA2G2A mRNA expression and 21% of 
sPLA2-IIa variance, yet accounted for only 0.5% of the vari-
ance of sPLA2 activity. In a similar fashion, the rs525380 SNP, 
which explained 15% of the variance of PLA2G5 mRNA, may 
only explain a small variance of sPLA2 activity (for which we 
may be underpowered to detect with precision in the current 
analysis). Thus, sPLA2-V may only make a minor contribu-
tion to plasma sPLA2 activity. An alternative explanation is 
that, despite rs525380 showing the strongest association with 
PLA2G5 mRNA in the aortic adventitia of the vasculature, 
rs525380 may not represent a suitable proxy for circulating 
sPLA2-V. The high level of expression of PLA2G5 mRNA in 
several relevant atherosclerosis-prone tissues, such as heart, 
mammary artery intima-media, ascending aorta intima-media, 
and aorta adventitia that we identified, suggest that sPLA2-V 
may have its greatest biological effect in these tissues and not 
in the plasma. Thus, circulating plasma sPLA2 activity may 
not reflect tissue levels of sPLA2-V.
PLA2G5 rs525380 showed a weak association with 
PLA2G2A expression in the liver but not in the other tissues 
we examined. This association could be a spurious find-
ing because it did not exceed the Bonferoni adjusted P value 
threshold. Alternatively, it could represent a real association. 
Our Bioinformatic analysis suggests that rs525380, 12.5 kb 
downstream of the PLA2G5, disrupts the binding site of the 
transcription factor GATA-2. GATA-2 is a transcription factor 
implicated in endothelial inflammatory responses.40 This might 
be particularly relevant to PLA2G5 given that Pla2g5  knockout 
mice show 50% reduction in eicosanoid generation in response 
to zymosan stimulus, thus suggesting that sPLA2-V plays an 
important role in innate immunity.12 The association of the 
PLA2G5 SNP rs525380 with PLA2G2A expression in the liver 
suggests that GATA-2 might also act as a transcription factor 
for the control of expression of PLA2G2A. However, although 
the rare A-allele of rs525380 is associated with higher PLA2G5 
expression levels, the common C allele is associated with 
higher PLA2G2A expression levels. We previously showed that 
of the 5 tissues available in ASAP, PLA2G2A was most highly 
expressed in the liver,41 a tissue that showed the lowest level 
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of PLA2G5 expression in this current study. This suggests a 
potential complementarity expression of these 2 transcripts in 
the liver, possibly under the control of GATA-2.
In conclusion, we identified no association between an 
SNP strongly linked to PLA2G5 mRNA tissue levels in 
 atherosclerosis-prone tissues and risk of CHD. Although the 
findings we report are by no means definitive, they do not sup-
port the hypothesis that sPLA2-V plays an important role in 
CHD. The methods we present demonstrate that in the absence 
of a specific plasma biomarker measure, it may be possible to 
use mRNA expression levels of the coding gene as a surrogate 
to examine the potential causal relationship of a biomarker.
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CLINICAL PERSPECTIVE
Secretory phospholipase (sPLA2) enzymes are thought to be involved in the development of coronary heart disease (CHD) 
through the synthesis of proinflammatory bioactive lipids and proatherogenic modification of low-density lipoprotein cho-
lesterol. Animal studies support a causal role of sPLA2-V in CHD; however, findings from animal studies do not always 
translate into humans. In an attempt to answer whether sPLA2-V is causally related to CHD in humans, we performed a 
modified Mendelian randomization study. Using a hypothesis-free approach, we identified the single-nucleotide polymor-
phism that associated most strongly with PLA2G5 mRNA expression (rs525380). We then investigated the association of 
this rs525380 single-nucleotide polymorphism with CHD in a pooled data set of >27 000 CHD cases and 70 000 controls 
and found no association with CHD (odds ratio per A-allele of rs525380 was 1.02; 95% confidence interval [0.99, 1.04]; 
P=0.20). This suggests that sPLA2-V is not causally related to CHD. The findings are of importance because a recent phase 
III randomized clinical trial of a drug that inhibits sPLA2-II, V, and X (varespladib) was terminated because of futility. Our 
previous Mendelian randomization analysis identified no causal effect of sPLA2-IIA on CHD, and this present study adds 
to it by suggesting that sPLA2-V is also noncausal for CHD. Taken together, the current evidence does not support a causal 
role for sPLA2 enzymes in CHD.
 at REYKJAVIK NATIONAL UNIVERSITY on May 4, 2015http://circgenetics.ahajournals.org/Downloaded from 
1 
 
SUPPLEMENTAL MATERIAL 
 
2 
 
 Supplementary Table 1. Characteristics of the studies used in the analyses. 
 
Study Study 
Design 
Geographic 
Location 
Sampling 
Frame 
Number of 
individuals 
CHD definition Baseline 
Year(s) 
% Female Age 
(Mean/SD) 
Genotype 
platform  
ADVANCE  C-C USA Electronic 
records 
590 Clinical non fatal CAD 
(men  
≤45 yrs, women ≤55 
yrs)  
including AMI 
(enzymes),  
typical angina with ≥1  
artery with >50% 
stenosis,  
positive non invasive 
test,  
or PCI or CABG 
2000 58.5 45.3 (5.7) Illumina 550k 
v3  
ASAP Cohort Sweden Single centre 
biobank 
272 Not CHD. Consecutive 
biobanking study of all 
individuals 
undergoing valve 
surgery at one clinic 
 
2007 28.7 63.6(12.4) Illumina 
Human 610W-
Quad Bead 
array 
CHARGE C-C Europe/USA 5 Prospective 
cohorts 
24311 CHD: definite or 
probable  
MI, PTCA or CABG, or  
ECG MI  
2007-
2008 
46.5 63.1 (8.0) Affymetrix 6.0 , 
Affymetrix 
500K, Illumina 
Infinium 
HumanHap 
550K 
deCODE C-C Iceland Icelandic 34251 MI: MONICA criteria 1998 49.1 53.7 (21.5) Illumina 
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population  (<75  
yrs) or discharge 
diagnosis  
of MI; CAD: PCI or  
participation in CVD  
genetics program with 
self report of CABG or 
PCI, or  
discharge diagnosis of  
angina pectoris, MI or  
chronic ischaemic 
heart  
disease 
HH300/ 
HHCNV370 
EPIC-Netherlands  Nested C-C Netherlands Existing 
cohorts 
5194 ICD-9:410; ICD-10: 
I21, I22 
1993-
1997 
78.11 54.0 (10.2) IBC CardioChip 
EPIC-Norfolk Nested C-C UK GPs 3039 ICD9 codes 410-414 1993-
1997 
34.65 64.7 (7.9) TaqMan 
GERMIFIS I  C-C Germany Multi-centre 2488 MI (<65 yrs) with >1 
1st 
degree sibling with 
severe  
CAD (PTCA; MI; CABG) 
1997-
2002 
50 62.6 (10.0) Affymetrix 
Mapping 500K 
Array Set 
GERMIFIS II  C-C Germany Multi-centre 2509 MI (<60 yrs); 59.4% 
with  
family history of CAD 
2002 40.7 51.2 (11.9) Affymetrix 
Genome-Wide 
Human SNP 
Array 6.0  
GERMIFIS III 
(KORA) 
C-C Germany Multi-centre 2905 MI (<60 yrs); MONICA  
criteria 
1999-
2001 
34.5 55.9 (10.7) Affymetrix 
Genome-Wide 
Human SNP 
Array 5.0 / 6.0 
CADomics C-C  Germany Single centre 5030 CAD: >50% stenosis in 
1 major coronary 
artery and/or MI 
1996-
1997 
38.7 55.3 (10.8)   Affymetrix 
Genome-Wide 
Human SNP 
4 
 
based on ECG and 
enzymes 
Array 6.0 
LURIC/ 
AtheroRemo 1  
C-C Germany Single centre 865 Symptoms of angina  
pectoris, NSTEMI, 
STEMI,  
or >50% coronary 
stenosis 
1997-
2002 
33.2 58.3 (12.1) Affymetrix 
Genome-Wide 
Human SNP 
Array 6.0 
LURIC/ 
AtheroRemo 2  
C-C Germany Single Centre 782 Symptoms of angina  
pectoris, NSTEMI, 
STEMI,  
or >50% coronary 
stenosis 
2002 36 56.4 (12.7) Affymetrix 
Mapping 500K 
Array Set 
MedStar  Cohort USA Single-centre 
hospital 
1322 Angiography (≥1 
coronary vessel with 
>50% stenosis); 
<65yrs 
2004-
2007 
54.59 59.7 (8.9) Affymetrix 
Genome-Wide  
Human SNP 
Array 6.0 
MIGEN C-C Europe/USA Multi-centre 2681 MI (men <50 yrs / 
women  
<60 yrs) 
1987-
1991 
38.6 43.0 (7.8) Affymetrix 
Genome-Wide 
Human SNP 
Array 6.0  
OHGS1  C-C Canada Single centre 2997 Angiographic (>50%  
stenosis) 
2010 36.1 75.0 (5.0) Affymetrix 
Mapping 500K 
Array Set / 
Genome-Wide 
Human SNP 
Array 6.0 
platform 
PennCath  C-C USA Single-centre 
hospital 
1516 Angiography (≥1 
coronary  
vessel with >50% 
stenosis);  
1998-
2003 
51.92 61.7 (9.6) Affymetrix 
Genome-Wide  
Human SNP 
Array 6.0 
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<65 yrs 
Whitehall II  Cohort UK Workplace 5018 ICD-9 codes 390.0–
458.9 and ICD-10 
codes I00–I99 
1985-
1988 
26.44 43.9 (5.9) IBC CardioChip 
Women’s Health 
Initiative 
Nested C-C USA Community 5729 Hospitalized MI 
and/or fatal CHD 
(death consistent with 
CHD as the underlying 
cause based on 
medical records and 
death certificate) 
1993-
1998 
100 68.0 (3.3) IBC CardioChip 
WTCCC  C-C UK 1958 Birth 
cohort and 
National blood 
donor register 
4864 Validated MI, CABG, 
PTCA  
or angina with 
positive noninvasive 
testing <66 yrs 
2005 35.4 49.8 (7.7) Affymetrix 
Mapping 500K  
Array Set 
Footnotes: CABG: coronary artery bypass graft; CAD: coronary artery disease; C-C: case control; ICD:  International Classification of Disease; 
MI: myocardial infarction; NSTEMI: non-ST-segment elevation myocardial infarction; PTCA: percutaneous transluminal coronary angioplasty, 
RCT: randomized clinical trial; STEMI: ST-segment elevation myocardial infarction  
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Supplementary Table 2 
The CARDIoGRAM Consortium 
Executive Committee: Sekar Kathiresan1,2,3, Muredach P. Reilly4, Nilesh J. Samani5,6, Heribert 
Schunkert7, Jeanette Erdmann7 
Steering Committee: Themistocles L. Assimes8, Eric Boerwinkle9, Jeanette Erdmann7, Alistair Hall10, 
Christian Hengstenberg11, Sekar Kathiresan1,2,3, Inke R. König12, Reijo Laaksonen13, Ruth McPherson14, 
Muredach P. Reilly4, Nilesh J. Samani5,6, Heribert Schunkert7, John R. Thompson15, Unnur 
Thorsteinsdottir16,17, Andreas Ziegler12 
Statisticians: Inke R. König12 (chair), John R. Thompson15 (chair), Devin Absher18, Li Chen19, L. 
Adrienne Cupples20,21, Eran Halperin22, Mingyao Li23, Kiran Musunuru1,2,3, Michael Preuss12,7, Arne 
Schillert12, Gudmar Thorleifsson16, Benjamin F. Voight2,3,24, George A. Wells25 
Writing group: Themistocles L. Assimes8, Panos Deloukas26, Jeanette Erdmann7, Hilma Holm16, Sekar 
Kathiresan1,2,3, Inke R. König12, Ruth McPherson14, Muredach P. Reilly4, Robert Roberts14, Nilesh J. 
Samani5,6, Heribert Schunkert7, Alexandre F. R. Stewart14 
ADVANCE: Devin Absher18, Themistocles L. Assimes8, Stephen Fortmann8, Alan Go27, Mark Hlatky8, 
Carlos Iribarren27, Joshua Knowles8, Richard Myers18, Thomas Quertermous8, Steven Sidney27, Neil 
Risch28, Hua Tang29 
CADomics: Stefan Blankenberg30, Tanja Zeller30, Arne Schillert12, Philipp Wild30, Andreas Ziegler12, 
Renate Schnabel30, Christoph Sinning30, Karl Lackner31, Laurence Tiret32, Viviane Nicaud32, Francois 
Cambien32, Christoph Bickel30, Hans J. Rupprecht30, Claire Perret32, Carole Proust32, Thomas Münzel30 
CHARGE: Maja Barbalic33, Joshua Bis34, Eric Boerwinkle9, Ida Yii-Der Chen35, L. Adrienne Cupples20,21, 
Abbas Dehghan36, Serkalem Demissie-Banjaw37,21, Aaron Folsom38, Nicole Glazer39, Vilmundur 
Gudnason40,41, Tamara Harris42, Susan Heckbert43, Daniel Levy21, Thomas Lumley44, Kristin 
Marciante45, Alanna Morrison46, Christopher J. O´Donnell47, Bruce M. Psaty48, Kenneth Rice49, Jerome 
I. Rotter35, David S. Siscovick50, Nicholas Smith43, Albert Smith40,41, Kent D. Taylor35, Cornelia van 
Duijn36, Kelly Volcik46, Jaqueline Whitteman36, Vasan Ramachandran51, Albert Hofman36, Andre 
Uitterlinden52,36 
deCODE: Solveig Gretarsdottir16, Jeffrey R. Gulcher16, Hilma Holm16, Augustine Kong16, Kari 
Stefansson16,17, Gudmundur Thorgeirsson53,17, Karl Andersen53,17, Gudmar Thorleifsson16, Unnur 
Thorsteinsdottir16,17 
GERMIFS I and II: Jeanette Erdmann7, Marcus Fischer11, Anika Grosshennig12,7, Christian 
Hengstenberg11, Inke R. König12, Wolfgang Lieb54, Patrick Linsel-Nitschke7, Michael Preuss12,7, Klaus 
Stark11, Stefan Schreiber55, H.-Erich Wichmann56,58,59, Andreas Ziegler12, Heribert Schunkert7 
GERMIFS III (KORA): Zouhair Aherrahrou7, Petra Bruse7, Angela Doering56, Jeanette Erdmann7, 
Christian Hengstenberg11, Thomas Illig56, Norman Klopp56, Inke R. König12, Patrick Linsel-Nitschke7, 
Christina Loley12,7, Anja Medack7, Christina Meisinger56, Thomas Meitinger57,60, Janja Nahrstedt12,7, 
Annette Peters56, Michael Preuss12,7, Klaus Stark11, Arnika K. Wagner7, H.-Erich Wichmann56,58,59, 
Christina Willenborg12,7, Andreas Ziegler12, Heribert Schunkert7 
LURIC/AtheroRemo: Bernhard O. Böhm61, Harald Dobnig62, Tanja B. Grammer63, Eran Halperin22, 
Michael M. Hoffmann64, Marcus Kleber65, Reijo Laaksonen13, Winfried März63,66,67, Andreas 
Meinitzer66, Bernhard R. Winkelmann68, Stefan Pilz62, Wilfried Renner66, Hubert Scharnagl66, Tatjana 
Stojakovic66, Andreas Tomaschitz62, Karl Winkler64 
MIGen: Benjamin F. Voight2,3,24, Kiran Musunuru1,2,3, Candace Guiducci3, Noel Burtt3, Stacey B. 
Gabriel3, David S. Siscovick50, Christopher J. O’Donnell47, Roberto Elosua69, Leena Peltonen49, Veikko 
Salomaa70, Stephen M. Schwartz50, Olle Melander26, David Altshuler71,3, Sekar Kathiresan1,2,3 
OHGS: Alexandre F. R. Stewart14, Li Chen19, Sonny Dandona14, George A. Wells25, Olga Jarinova14, 
Ruth McPherson14, Robert Roberts14 
PennCATH/MedStar: Muredach P. Reilly4, Mingyao Li23, Liming Qu23, Robert Wilensky4, William 
Matthai4, Hakon H. Hakonarson72, Joe Devaney73, Mary Susan Burnett73, Augusto D. Pichard73, 
Kenneth M. Kent73, Lowell Satler73, Joseph M. Lindsay73, Ron Waksman73, Christopher W. Knouff74, 
Dawn M. Waterworth74, Max C. Walker74, Vincent Mooser74, Stephen E. Epstein73, Daniel J. Rader75,4 
7 
 
WTCCC: Nilesh J. Samani5,6, John R. Thompson15, Peter S. Braund5, Christopher P. Nelson5, Benjamin 
J. Wright76, Anthony J. Balmforth77, Stephen G. Ball78, Alistair S. Hall10, Wellcome Trust Case Control 
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Supplementary Figures 
Supplementary Figure 1 Regional haploblock plot of PLA2G5 rs525380 showing low linkage disequilibrium with closely linked PLA2G2A 
SNPs. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Footnote: Representing Caucasian (CEU) data  
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Supplementary Figure 2 Bioinformatic details of rs525380 in intron 1, identifying position relative to GATA-2 and a DNAse hypersensitive 
region.  There is no evidence that this SNP affects splicing. Taken from www.genome.ucsc.edu 
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Supplementary Figure 3. Association of PLA2G5 rs525380 with PLA2G2A mRNA 
expression in the liver.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Footnote: P=0.001 for differential expression by rs525380, using an additive model. 
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